New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
13:39 EDTTMO, BRKR, PKIThermo Fisher Q2 results bode well for PerkinElmer, Bruker, says Mizuho
After Thermo Fisher reported Q2 earnings and revenue that beat consensus, Mizuho said all but the Diagnostics segment had results above the firm's expectations and that the company's guidance raise was larger than it first appears after its Cole-Parmer divestiture is accounted for. Mizuho maintains its Buy rating and $150 price target on Thermo Fisher and said its results bode well for PerkinElmer (PKI) and Bruker (BRKR).
News For TMO;PKI;BRKR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
07:41 EDTTMOEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
10:16 EDTTMOHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
April 6, 2015
10:02 EDTBRKROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:22 EDTTMOBofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
08:02 EDTBRKRBruker upgraded to Outperform with $24 price target at Leerink
Leerink upgraded Bruker to Outperform from Market Perform saying it sees share upside from the company's operational improvements and better competitive position in nuclear magnetic resonance instruments. The firm raised its price target for shares to $24 from $21.
05:42 EDTBRKRBruker upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
April 5, 2015
12:47 EDTBRKRBruker gets FDA clearance for 2nd expanded claim for MALDI Biotyper CA System
Bruker announced that it has received 510(k) clearance from the US Food and Drug Administration for library and methods expansion for the MALDI Biotyper CA System, sold in the United States for clinical microbiology. In November 2013, Bruker received FDA 510(k) clearance for a first claim for the MALDI Biotyper CA System, an IVD solution, which included Brukerís global market leading MALDI Biotyper instrumentation; software; a library of 40 aerobic Gram negative bacterial species or species groups, covering 100 clinically relevant species; in vitro diagnostic reagents; and standard operating procedures. The recent clearance of a second, expanded claim now adds 170 species and species groups, representing 180 clinically-relevant species of aerobic Gram positive, fastidious Gram negatives, Enterobacteriaceae, anaerobic bacteria and yeasts. In addition, customers will have additional specimen preparation options to further optimize workflows. As a result of the latest 510(k) clearance, the MALDI Biotyper CA System can now in total identify 210 species or species groups, covering 280 clinically relevant bacteria and yeast species, and representing more than 98% of the typical bacterial identification workflow of clinical microbiology laboratories.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use